CN111904979A - 一种促进伤口愈合的中药散剂及其制备方法 - Google Patents
一种促进伤口愈合的中药散剂及其制备方法 Download PDFInfo
- Publication number
- CN111904979A CN111904979A CN202010802697.XA CN202010802697A CN111904979A CN 111904979 A CN111904979 A CN 111904979A CN 202010802697 A CN202010802697 A CN 202010802697A CN 111904979 A CN111904979 A CN 111904979A
- Authority
- CN
- China
- Prior art keywords
- traditional chinese
- parts
- chinese medicine
- wound
- promoting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000843 powder Substances 0.000 title claims abstract description 39
- 239000003814 drug Substances 0.000 title claims abstract description 28
- 230000001737 promoting effect Effects 0.000 title claims abstract description 24
- 230000029663 wound healing Effects 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 53
- 206010052428 Wound Diseases 0.000 claims abstract description 52
- UKWHYYKOEPRTIC-UHFFFAOYSA-N mercury(ii) oxide Chemical compound [Hg]=O UKWHYYKOEPRTIC-UHFFFAOYSA-N 0.000 claims abstract description 34
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 24
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 20
- 229940116229 borneol Drugs 0.000 claims abstract description 20
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 20
- 229940105847 calamine Drugs 0.000 claims abstract description 20
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 20
- 229910052864 hemimorphite Inorganic materials 0.000 claims abstract description 20
- 239000011787 zinc oxide Substances 0.000 claims abstract description 20
- 235000014692 zinc oxide Nutrition 0.000 claims abstract description 20
- CPYIZQLXMGRKSW-UHFFFAOYSA-N zinc;iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+3].[Fe+3].[Zn+2] CPYIZQLXMGRKSW-UHFFFAOYSA-N 0.000 claims abstract description 20
- 229940101209 mercuric oxide Drugs 0.000 claims abstract description 17
- 208000014674 injury Diseases 0.000 claims abstract description 6
- 230000008733 trauma Effects 0.000 claims abstract description 5
- 208000002249 Diabetes Complications Diseases 0.000 claims abstract description 4
- 206010012655 Diabetic complications Diseases 0.000 claims abstract description 4
- 238000000227 grinding Methods 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 7
- 238000007789 sealing Methods 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 3
- 230000035876 healing Effects 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 6
- 206010061218 Inflammation Diseases 0.000 abstract description 5
- 230000004054 inflammatory process Effects 0.000 abstract description 5
- 230000008901 benefit Effects 0.000 abstract description 4
- 206010061926 Purulence Diseases 0.000 abstract description 2
- 230000003467 diminishing effect Effects 0.000 abstract description 2
- 235000013372 meat Nutrition 0.000 abstract description 2
- 230000001988 toxicity Effects 0.000 abstract description 2
- 231100000419 toxicity Toxicity 0.000 abstract description 2
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 238000005303 weighing Methods 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 239000004744 fabric Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000000472 traumatic effect Effects 0.000 description 3
- 229920000742 Cotton Polymers 0.000 description 2
- 206010039509 Scab Diseases 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000001804 debridement Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 208000032544 Cicatrix Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000000459 calcaneus Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 210000000474 heel Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000018040 scab formation Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000003966 vascular damage Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/28—Mercury; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明实施例公开了一种促进伤口愈合的中药散剂及其制备方法，属于中药技术领域。一种促进伤口愈合的中药散剂，由以下重量份数的组分制成：红升丹0.8‑1.2份、冰片0.8‑1.2份、炉甘石16‑20份。本发明促进伤口愈合的中药散剂以红升丹、冰片、炉甘石按照一定配比制成，其中，红升丹祛毒去腐，促进伤口新肉的生成；冰片清热、化脓、消炎；炉甘石拔毒化腐生肌药，本发明的中药散剂对久治不愈的外伤伤口和糖尿病并发症伤口均具有较好的促进愈合作用，同时还具有使用方便的优点。
Description
技术领域
本发明实施例涉及中药技术领域，具体涉及一种促进伤口愈合的中药散剂及其制备方法。
背景技术
皮肤是我们身体的保护屏障，同时也非常脆弱，在生活中经常会有各种各样的原因让皮肤留下伤口。如果伤口小，处理得当，会很快愈合，但是如果伤口较深较大，处理不及时或处理方法不恰当，会引起伤口出血、感染、化脓，伤口迟迟不能愈合。
一般来说，正常伤口愈合从新鲜伤口、愈合伤口到结疤的过程分三个阶段：收缩与炎症反应阶段、形成肉芽组织修复、组织重建形成瘢痕。其中，收缩与炎症反应阶段非常重要，收缩可避免损伤后过多出血，炎症反应的作用主要是保护机体，防止严重的合并症，如脓血症。
伤口长期不能愈合的原因包括：伤口部位的血液供应较差；伤口部位的血管损伤较严重；湿热等体质的人外伤后，伤口局部的炎性介质较多，新生小血管发生炎性水肿，对伤口的愈合也有很大影响。
目前，临床上对伤口的处理包括常规的清创缝合及抗菌治疗，存在伤口愈合困难、久愈不合的缺陷。
发明内容
为此，本发明实施例提供一种促进伤口愈合的中药散剂及其制备方法，以解决现有伤口愈合困难、久愈不合的问题。
为了实现上述目的，本发明实施例提供如下技术方案：
根据本发明实施例的第一方面，本发明实施例提供一种促进伤口愈合的中药散剂，由以下重量份数的组分制成：红升丹0.8-1.2份、冰片0.8-1.2份、炉甘石16-20份。
进一步地，由以下重量份数的组分制成：红升丹1份、冰片1份、炉甘石18份。
红升丹：去腐，用于久不收口。现代药理研究证实，红升丹对绿脓杆菌、大肠杆菌、金黄色葡萄球菌等都有抑制作用。本申请使用的红升丹为粉剂，采购于自中药材市场。
冰片：有抑菌作用，抑制炎性因子对疮面的刺激，使得局部的微循环血管的炎性水肿减轻，疮面修复得以正常进行，疮口顺利结痂愈合。
炉甘石：具有抑菌作用，能杀灭局部葡萄球菌，并毫无刺激性；对疮面有收敛、防腐、保护作用。使得疮面水肿的微循环小血管恢复正常，从而加速疮口愈合。
根据本发明实施例的第二方面，本发明实施例提供一种上述的促进伤口愈合的中药散剂的制备方法，包括以下步骤：
1)将冰片、炉甘石分别研磨成细粉备用；
2)红升丹、冰片和炉甘石按照重量配比进行混合，搅拌均匀，密封装瓶。
进一步地，细粉粒径为200-400目。
根据本发明实施例的第三方面，本发明实施例提供上述的中药散剂在制备用于促进伤口愈合的药物中的应用。
进一步地，所述伤口包括久治不愈的外伤伤口和糖尿病并发症伤口。
外伤伤口是指身体由于外界物体的打击、碰撞或化学物质的侵蚀等形成的破裂地方，多指人或其他动物的皮肤、肌肉、黏膜等。本发明中的外伤伤口不包括烧伤。
糖尿病患者因为血液含糖过高，导致携带氧气和营养物质的能力下降，伤口不易愈合。另外，血糖高导致破损部位极易滋生微生物，诱发感染。
本发明中药散剂的使用方法：伤口疮面消毒清创后，将药粉均匀地撒满疮面，用无菌薄纱布或棉布包扎伤口，次日打开包扎布，向湿润疮面再次撒药粉，此时不需要清创，换一块新的无菌薄纱布或棉布覆盖疮面，隔日发现有湿润疮面，按上述操作进行即可。
适用范围：本申请的中药散剂特别适用于长期不愈的外伤疮口，也用于糖尿病所致的难以愈合的伤口。日常生活中小磕碰的伤口使用更简单，伤口用碘伏或酒精消毒，用点生理盐水冲洗创面后，撒上药粉，用创可贴包上就行，这样能有效防止创可贴使用时间过长而引发伤口感染的副作用。
本发明中药散剂为外用制剂，主要用于外伤后，创口经正规处理及用药治疗2个月后，疮口基本情况无改善或疮口不愈合的病人，也可用于普通的皮肤小伤口。禁忌：有缝合线的创面禁忌使用(因为该药粉是促进疮口结痂，从而会使缝合线和痂粘结在一起，拆线后可正常使用)。
本发明实施例具有如下优点：
本发明促进伤口愈合的中药散剂以红升丹、冰片、炉甘石按照一定配比制成，其中，红升丹祛毒去腐，促进伤口新肉的生成；冰片清热、化脓、消炎；炉甘石拔毒化腐生肌药，本发明的中药散剂对外伤和糖尿病并发症产生的伤口均具有较好的促进愈合作用，同时还具有使用方便的优点。
具体实施方式
以下由特定的具体实施例说明本发明的实施方式，熟悉此技术的人士可由本说明书所揭露的内容轻易地了解本发明的其他优点及功效，显然，所描述的实施例是本发明一部分实施例，而不是全部的实施例。基于本发明中的实施例，本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例，都属于本发明保护的范围。
实施例1
本实施例的促进伤口愈合的中药散剂的制备方法包括以下步骤：
1)将冰片、炉甘石分别研磨成粒径为200目的细粉备用；
2)称量红升丹0.8份、冰片1份和炉甘石20份，混合，搅拌均匀，密封装瓶。
实施例2
本实施例的促进伤口愈合的中药散剂的制备方法包括以下步骤：
1)将冰片、炉甘石分别研磨成粒径为200-400目的细粉备用；
2)称量红升丹1份、冰片1份和炉甘石18份，混合，搅拌均匀，密封装瓶。
实施例3
本实施例的促进伤口愈合的中药散剂的制备方法包括以下步骤：
1)将冰片、炉甘石分别研磨成粒径为400目的细粉备用；
2)称量红升丹1.2份、冰片1份和炉甘石16份，混合，搅拌均匀，密封装瓶。
实施例4
本实施例的促进伤口愈合的中药散剂的制备方法包括以下步骤：
1)将冰片、炉甘石分别研磨成粒径为300目的细粉备用；
2)称量红升丹1份、冰片0.8份和炉甘石16份，混合，搅拌均匀，密封装瓶。
实施例5
本实施例的促进伤口愈合的中药散剂的制备方法包括以下步骤：
1)将冰片、炉甘石分别研磨成粒径为200目的细粉备用；
2)称量红升丹1份、冰片1.2份和炉甘石20份，混合，搅拌均匀，密封装瓶。
典型案例：
唐国元，男，53岁，2008年因所乘坐的摩托翻车致右下肢跟骨部皮肤擦裂伤，在丰城市人民医院住院治疗7天后病人除右跟股部的疮口未愈合外，无其他不适，继续住院治疗右跟骨部疮口40多天仍未能收口，病人打听本申请的药物对不能收口的疮口有奇效而前来就医，经门诊清洁创面后，撒上药粉，用薄纱布敷料盖住撒药的创面，叮嘱其第二天如发现创面有渗湿的地方撒上药粉就行，没有湿的地方就不要动他，15天后回访病人，创面已收口，正在剥去痂皮。
虽然，上文中已经用一般性说明及具体实施例对本发明作了详尽的描述，但在本发明基础上，可以对之作一些修改或改进，这对本领域技术人员而言是显而易见的。因此，在不偏离本发明精神的基础上所做的这些修改或改进，均属于本发明要求保护的范围。
Claims (6)
1.一种促进伤口愈合的中药散剂，其特征在于，由以下重量份数的组分制成：红升丹0.8-1.2份、冰片0.8-1.2份、炉甘石16-20份。
2.根据权利要求1所述的促进伤口愈合的中药散剂，其特征在于，由以下重量份数的组分制成：红升丹1份、冰片1份、炉甘石18份。
3.一种权利要求1所述的中药散剂的制备方法，其特征在于，包括以下步骤：
1)将冰片、炉甘石分别研磨成细粉备用；
2)红升丹、冰片和炉甘石按照重量配比进行混合，搅拌均匀，密封装瓶。
4.根据权利要求3所述的制备方法，其特征在于，细粉粒径为200-400目。
5.权利要求1所述的中药散剂在制备用于促进伤口愈合的药物中的应用。
6.根据权利要求5所述的应用，其特征在于，所述伤口包括久治不愈的外伤伤口和糖尿病并发症伤口。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010802697.XA CN111904979A (zh) | 2020-08-11 | 2020-08-11 | 一种促进伤口愈合的中药散剂及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010802697.XA CN111904979A (zh) | 2020-08-11 | 2020-08-11 | 一种促进伤口愈合的中药散剂及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111904979A true CN111904979A (zh) | 2020-11-10 |
Family
ID=73283880
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010802697.XA Pending CN111904979A (zh) | 2020-08-11 | 2020-08-11 | 一种促进伤口愈合的中药散剂及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111904979A (zh) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1857318A (zh) * | 2006-04-14 | 2006-11-08 | 刘皇琼 | 一种外伤快速愈合复方中药散剂及其制备方法 |
| CN100998604A (zh) * | 2007-01-08 | 2007-07-18 | 杜伟 | 一种治疗烧伤烫伤的中药及其制备方法 |
-
2020
- 2020-08-11 CN CN202010802697.XA patent/CN111904979A/zh active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1857318A (zh) * | 2006-04-14 | 2006-11-08 | 刘皇琼 | 一种外伤快速愈合复方中药散剂及其制备方法 |
| CN100998604A (zh) * | 2007-01-08 | 2007-07-18 | 杜伟 | 一种治疗烧伤烫伤的中药及其制备方法 |
Non-Patent Citations (6)
| Title |
|---|
| 庄廷芳，林定周: "炉甘石散对烧伤残余创面的疗效观察", 《辽宁中医杂志》 * |
| 彭怀仁: "《中医方剂大辞典 第四册》", 28 February 1995, 人民卫生出版社 * |
| 李今庸: "《李今庸临床医论医话》", 31 July 2017, 中国中医药出版社 * |
| 李瑞: "冰矾炉甘散外用治疗糖尿病足部溃疡56例", 《中医外治杂志》 * |
| 谢礼献: ""炉冰散"的临床运用", 《四川中医》 * |
| 陈加龙: "祛腐生肌散治疗伤口久溃不敛173例", 《陕西中医》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Molan | Why honey is effective as a medicine. 1. Its use in modern medicine | |
| Simon et al. | Medical honey for wound care—still the ‘latest resort’? | |
| EP2815754B1 (en) | Composition for treating biofilm-based infections | |
| US20040131693A1 (en) | Composition with a base of a therapeutically active compound, in particular honey, for the treatment of wounds | |
| Doanh et al. | The use of a water extract from the bark of Choerospondias axillaris in the treatment of second decree burns | |
| WO2020144564A1 (en) | Composition for the treatment of skin lesions and irritations | |
| CN109432483B (zh) | 一种加速创面愈合的医用敷料及其制备方法和应用 | |
| Lobo Gajiwala et al. | Use of irradiated amnion as a biological dressing in the treatment of radiation induced ulcers | |
| CN112933214A (zh) | 一种促进伤口愈合的组合物 | |
| CN103690903B (zh) | 一种治疗烧烫伤褥疮等外伤疾病的复方中药制剂 | |
| EP3710044B1 (en) | Wound treatment containing collagen and a gelatin-reducing agent, and method for promoting wound healing | |
| CN100425238C (zh) | 一种烧伤药物粉剂 | |
| CN111904979A (zh) | 一种促进伤口愈合的中药散剂及其制备方法 | |
| RU2528905C1 (ru) | Способ лечения ран мягких тканей различной этиологии | |
| CN110251716B (zh) | 一种伤口护理用凝胶敷料及其制备方法 | |
| CN109674743B (zh) | 一种伤口护理凝胶及其制备方法 | |
| CN108635362B (zh) | 一种治疗糖尿病足的药物组合物 | |
| Mahmood et al. | Evaluation of in vivo wound healing activity of Chromolaena odorata leaf extract on excision wounds model in rats | |
| CN1186068C (zh) | 具有消炎生肌止痒止痛作用的外用中成药及其制备方法 | |
| Thornton et al. | Case report: maggot therapy in an acute burn | |
| Emadi et al. | Efficacy of a novel repairing gel therapy for the management of chronic wounds: a single-center, self-controlled pilot trial | |
| Harsono et al. | Randomized Control Trial Comparing Moist Exposed Burn Ointment and Honey as Dressings Agents in Patients with Second-Degree Burns | |
| EP4284339A1 (en) | Powdered collagen wound care compositions | |
| Budiharto et al. | Wound Care Management in Infants with Congenital Abnormalities at the Wound and Stoma Clinic RSUD dr Soedarso Pontianak | |
| CN104739856B (zh) | 蒙脱石外用散剂在制备治疗皮肤溃疡的药物中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |